220 related articles for article (PubMed ID: 33385585)
21. Commercial anti-CD19 CAR T cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European center.
Sesques P; Ferrant E; Safar V; Wallet F; Tordo J; Dhomps A; Karlin L; Brisou G; Vercasson M; Hospital-Gustem C; Schwiertz V; Ranchon F; Rioufol C; Choquet M; Sujobert P; Ghergus D; Bouafia F; Golfier C; Lequeu H; Lazareth A; Novelli S; Devic P; Traverse Glehen A; Viel S; Venet F; Mialou V; Hequet O; Chauchet A; Arkam Y; Nicolas-Virelizier E; Peyrade F; Cavalieri D; Ader F; Ghesquières H; Salles G; Bachy E
Am J Hematol; 2020 Nov; 95(11):1324-1333. PubMed ID: 32744738
[TBL] [Abstract][Full Text] [Related]
22. Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma.
Scholler N; Perbost R; Locke FL; Jain MD; Turcan S; Danan C; Chang EC; Neelapu SS; Miklos DB; Jacobson CA; Lekakis LJ; Lin Y; Ghobadi A; Kim JJ; Chou J; Plaks V; Wang Z; Xue A; Mattie M; Rossi JM; Bot A; Galon J
Nat Med; 2022 Sep; 28(9):1872-1882. PubMed ID: 36038629
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and Safety of Axicabtagene Ciloleucel and Tisagenlecleucel Administration in Lymphoma Patients With Secondary CNS Involvement: A Systematic Review.
Wu X; Zhang X; Xun R; Liu M; Sun Z; Huang J
Front Immunol; 2021; 12():693200. PubMed ID: 34290712
[TBL] [Abstract][Full Text] [Related]
24. Outcomes and factors impacting use of axicabtagene ciloleucel in patients with relapsed or refractory large B-cell lymphoma: results from an intention-to-treat analysis.
Mian A; Wei W; Winter AM; Khouri J; Jagadeesh D; Anwer F; Gerds AT; Dean RM; Sobecks R; Pohlman B; Hamilton BK; Majhail NS; Hill BT
Leuk Lymphoma; 2021 Jun; 62(6):1344-1352. PubMed ID: 33375873
[TBL] [Abstract][Full Text] [Related]
25. Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma.
Kwon M; Iacoboni G; Reguera JL; Corral LL; Morales RH; Ortiz-Maldonado V; Guerreiro M; Caballero AC; Domínguez MLG; Pina JMS; Mussetti A; Sancho JM; Bastos-Oreiro M; Catala E; Delgado J; Henriquez HL; Sanz J; Calbacho M; Bailén R; Carpio C; Ribera JM; Sureda A; Briones J; Hernandez-Boluda JC; Cebrián NM; Martin JLD; Martín A; Barba P
Haematologica; 2023 Jan; 108(1):110-121. PubMed ID: 35770532
[TBL] [Abstract][Full Text] [Related]
26. Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma.
Haradhvala NJ; Leick MB; Maurer K; Gohil SH; Larson RC; Yao N; Gallagher KME; Katsis K; Frigault MJ; Southard J; Li S; Kann MC; Silva H; Jan M; Rhrissorrakrai K; Utro F; Levovitz C; Jacobs RA; Slowik K; Danysh BP; Livak KJ; Parida L; Ferry J; Jacobson C; Wu CJ; Getz G; Maus MV
Nat Med; 2022 Sep; 28(9):1848-1859. PubMed ID: 36097221
[TBL] [Abstract][Full Text] [Related]
27. A national service for delivering CD19 CAR-Tin large B-cell lymphoma - The UK real-world experience.
Kuhnl A; Roddie C; Kirkwood AA; Tholouli E; Menne T; Patel A; Besley C; Chaganti S; Sanderson R; O'Reilly M; Norman J; Osborne W; Bloor A; Lugthart S; Malladi R; Patten PEM; Neill L; Martinez-Cibrian N; Kennedy H; Phillips EH; Jones C; Sharplin K; El-Sharkawi D; Latif AL; Mathew A; Uttenthal B; Stewart O; Marzolini MAV; Townsend W; Cwynarski K; Ardeshna K; Ardavan A; Robinson K; Pagliuca A; Collins GP; Johnson R; McMillan A
Br J Haematol; 2022 Aug; 198(3):492-502. PubMed ID: 35485402
[TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness of axicabtagene ciloleucel for adult patients with relapsed or refractory large B-cell lymphoma in the United States.
Roth JA; Sullivan SD; Lin VW; Bansal A; Purdum AG; Navale L; Cheng P; Ramsey SD
J Med Econ; 2018 Dec; 21(12):1238-1245. PubMed ID: 30260711
[TBL] [Abstract][Full Text] [Related]
29. Severity of Cytokine Release Syndrome Influences Outcome After Axicabtagene Ciloleucel for Large B cell Lymphoma: Results from the US Lymphoma CAR-T Consortium.
Jacobs MT; Jain MD; Gao F; Nastoupil LJ; Spiegel JY; Lin Y; Dahiya S; Lunning M; Lekakis L; Reagan PM; Oluwole OO; McGuirk J; Deol A; Sehgal A; Goy A; Hill BT; Andreadis C; Munoz J; Chavez JC; Bennani NN; Rapoport AP; Vose JM; Miklos DB; Neelapu SS; Ghobadi A; Locke FL
Clin Lymphoma Myeloma Leuk; 2022 Oct; 22(10):753-759. PubMed ID: 35780055
[TBL] [Abstract][Full Text] [Related]
30. Safety of Axicabtagene Ciloleucel for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma.
Grana A; Gut N; Williams K; Maakaron J; Porter K; William BM; Vasu S; Penza S; Brammer JE; Saad A; Puto M; Jaglowski SM; Roddy J
Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):238-245. PubMed ID: 33132101
[TBL] [Abstract][Full Text] [Related]
31. Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma.
Topp MS; van Meerten T; Houot R; Minnema MC; Bouabdallah K; Lugtenburg PJ; Thieblemont C; Wermke M; Song KW; Avivi I; Kuruvilla J; Dührsen U; Zheng Y; Vardhanabhuti S; Dong J; Bot A; Rossi JM; Plaks V; Sherman M; Kim JJ; Kerber A; Kersten MJ
Br J Haematol; 2021 Nov; 195(3):388-398. PubMed ID: 34590303
[TBL] [Abstract][Full Text] [Related]
32. Effect of delayed cell infusion in patients with large B-cell lymphoma treated with chimeric antigen receptor T-cell therapy.
Jallouk AP; Kui N; Sun R; Westin JR; Steiner RE; Nair R; Nastoupil LJ; Fayad LE; Zaki AA; Hawkins M; Adkins S; Noorani M; Das K; Henderson J; Shpall EJ; Kebriaei P; Ramdial J; Flowers CR; Neelapu SS; Ahmed S; Strati P
Haematologica; 2024 May; 109(5):1460-1468. PubMed ID: 38031807
[TBL] [Abstract][Full Text] [Related]
33. Monitoring of Circulating Tumor DNA Improves Early Relapse Detection After Axicabtagene Ciloleucel Infusion in Large B-Cell Lymphoma: Results of a Prospective Multi-Institutional Trial.
Frank MJ; Hossain NM; Bukhari A; Dean E; Spiegel JY; Claire GK; Kirsch I; Jacob AP; Mullins CD; Lee LW; Kong KA; Craig J; Mackall CL; Rapoport AP; Jain MD; Dahiya S; Locke FL; Miklos DB
J Clin Oncol; 2021 Sep; 39(27):3034-3043. PubMed ID: 34133196
[TBL] [Abstract][Full Text] [Related]
34. Feasibility and Safety of CD19 Chimeric Antigen Receptor T Cell Treatment for B Cell Lymphoma Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.
Schubert ML; Dietrich S; Stilgenbauer S; Schmitt A; Pavel P; Kunz A; Bondong A; Wegner M; Stadtherr P; Jung S; Ho AD; Müller-Tidow C; Schmitt M; Dreger P
Biol Blood Marrow Transplant; 2020 Sep; 26(9):1575-1580. PubMed ID: 32422254
[TBL] [Abstract][Full Text] [Related]
35. Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Multiply Relapsed or Refractory Adult Large B-Cell Lymphoma.
Lin JK; Muffly LS; Spinner MA; Barnes JI; Owens DK; Goldhaber-Fiebert JD
J Clin Oncol; 2019 Aug; 37(24):2105-2119. PubMed ID: 31157579
[TBL] [Abstract][Full Text] [Related]
36. Predictors of response to axicabtagene-ciloleucel CAR T cells in aggressive B cell lymphomas: A real-world study.
Iovino L; Wu QV; Voutsinas J; Panaite L; Mullane E; Lynch RC; Ujjani C; Smith SD; Gopal AK; Till BG; Milano F; Chow V; Gauthier J; Turtle CJ; Maloney DG; Shadman M
J Cell Mol Med; 2022 Dec; 26(24):5976-5983. PubMed ID: 36453136
[TBL] [Abstract][Full Text] [Related]
37. Neurological adverse events following CAR T-cell therapy: a real-world analysis.
Gajra A; Zettler ME; Phillips EG; Klink AJ; Jonathan K Kish ; Fortier S; Mehta S; Feinberg BA
Immunotherapy; 2020 Oct; 12(14):1077-1082. PubMed ID: 32808566
[No Abstract] [Full Text] [Related]
38. Phase 2 study of axicabtagene ciloleucel in Japanese patients with relapsed or refractory large B-cell lymphoma.
Kato K; Makita S; Goto H; Kanda J; Fujii N; Shimada K; Akashi K; Izutsu K; Teshima T; Fukuda N; Sumitani T; Sumi H; Shimizu S; Kakurai Y; Yoshikawa K; Tobinai K; Usui N; Hatake K
Int J Clin Oncol; 2022 Jan; 27(1):213-223. PubMed ID: 34599413
[TBL] [Abstract][Full Text] [Related]
39. Phenotypic Composition of Commercial Anti-CD19 CAR T Cells Affects In Vivo Expansion and Disease Response in Patients with Large B-cell Lymphoma.
Monfrini C; Stella F; Aragona V; Magni M; Ljevar S; Vella C; Fardella E; Chiappella A; Nanetti F; Pennisi M; Dodero A; Guidetti A; Corradini P; Carniti C
Clin Cancer Res; 2022 Aug; 28(15):3378-3386. PubMed ID: 35583610
[TBL] [Abstract][Full Text] [Related]
40. Impact of tumor microenvironment on efficacy of anti-CD19 CAR T cell therapy or chemotherapy and transplant in large B cell lymphoma.
Locke FL; Filosto S; Chou J; Vardhanabhuti S; Perbost R; Dreger P; Hill BT; Lee C; Zinzani PL; Kröger N; López-Guillermo A; Greinix H; Zhang W; Tiwari G; Budka J; Marincola FM; To C; Mattie M; Schupp M; Cheng P; Bot A; Shen R; Bedognetti D; Miao H; Galon J
Nat Med; 2024 Feb; 30(2):507-518. PubMed ID: 38233586
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
